Atlas Trials

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

Clinical trial NCT04633447 · TERMINATED

Trial details

NCT number
NCT04633447
Sponsor
Janssen Research & Development, LLC
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Giant Cell Arteritis
Start date
2020-12-10
Primary completion
2024-05-22
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.